A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Crohn's Disease

In brief

This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.

Key facts

Study ID

NCT06958536

Run by

Sanofi

People needed

99

Starts

2025-06-03

Expected to finish

2029-10-17

Last updated by the study team

2026-03-27

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Crohn's Disease (CD) for at least 3 months prior to screening
• Confirmed diagnosis of moderate-to-severe CD
• History of prior exposure to standard treatment (5-Amino Salicylates (5-ASAs), steroids, immunomodulators or antibiotics) or advanced therapies (ATs) (biologics or small molecules), but having inadequate response to, loss or response to or intolerance to at least one of these therapies
• On stable doses of standard treatments prior to screening (Oral 5-ASA compounds, Oral corticosteroids, Azathioprine (AZA), 6-Mercaptopurine (6-MP), or Methotrexate (MTX), or Antibiotics, etc.)
• Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies

You may not qualify if…

• Participants with active Ulcerative Colitis (UC), indeterminate colitis, adenomatous colonic polyps not excised, colonic mucosal dysplasia (low- or high-grade dysplasia) or short bowel syndrome
• Participants with CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic or ileal involvement
• Participants with following ongoing known complications of CD:
• Any manifestation that might require bowel surgery while enrolled in the study
• Participant with ostomy or ileoanal pouch
• Participant diagnosed with conditions that could interfere with drug absorption including but not limited to short bowel syndrome
• Participant with surgical bowel resection within the past three months prior to screening, or a history of >3 bowel resections
• History of any other condition which, in the opinion of the Investigator, would put the participant at risk by participation in the study
• The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Where it is running

• Investigational Site Number: 8400005 — Escondido, California, United States (enrolling)
• Investigational Site Number: 8400001 — Lancaster, California, United States (enrolling)
• Investigational Site Number: 8400017 — Kissimmee, Florida, United States (enrolling)
• Investigational Site Number: 8400015 — Lighthouse PT, Florida, United States (enrolling)
• Investigational Site Number 8400028 — Miami, Florida, United States (enrolling)
• Investigational Site Number: 8400012 — Miami, Florida, United States (enrolling)
• Investigational Site Number: 8400007 — Orlando, Florida, United States (enrolling)
• Investigational Site Number: 8400011 — Palmetto Bay, Florida, United States (enrolling)
• Investigational Site Number: 8400019 — Marietta, Georgia, United States (enrolling)
• Investigational Site Number: 8400025 — Iowa City, Iowa, United States (enrolling)
• Investigational Site Number: 8400006 — Kansas City, Kansas, United States (enrolling)
• Investigational Site Number: 8400022 — Boston, Massachusetts, United States (enrolling)
• Investigational Site Number: 8400008 — Wyoming, Michigan, United States (enrolling)
• Investigational Site Number: 8400013 — St Louis, Missouri, United States (enrolling)
• Investigational Site Number: 8400003 — Chapel Hill, North Carolina, United States (enrolling)
• Investigational Site Number: 8400009 — Harrisburg, Pennsylvania, United States (enrolling)
• Investigational Site Number: 8400002 — Fredericksburg, Texas, United States (enrolling)
• Investigational Site Number: 8400016 — Ogden, Utah, United States (enrolling)
• Investigational Site Number: 8400027 — Richmond, Virginia, United States (enrolling)
• Investigational Site Number: 0360002 — Brisbane, Queensland, Australia (enrolling)
• Investigational Site Number: 0360004 — Kurralta Park, South Australia, Australia (enrolling)
• Investigational Site Number: 0360001 — Footscray, Australia (enrolling)
• Investigational Site Number: 0560001 — Leuven, Belgium (enrolling)
• Investigative Site: 1560003 — Changsha, China (enrolling)
• Investigational Site Number: 8400024 — Tucson, Arizona, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.